Özlem Sever

13PUBLICATIONS
64CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Feb 26, 2026
Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer.

Akif Doğan, Hande Nur Erölmez, Goncagül Akdağ

|Oct 16, 2025
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage.

Tugba Basoglu, Ugur Ozkerim, Sila Oksuz

|May 06, 2025
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Sedat Yıldırım, Tugba Başoğlu, Akif Doğan

|Feb 26, 2025
Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer.

Özlem Nuray Sever, Tuğba Başoğlu, Sedat Yıldırım

|Jan 25, 2025
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study.

Akif Doğan, Nurullah İlhan, Goncagül Akdağ

Pageof 3

Frequent Collaborators

10 joint publications

Sedat Yıldırım

8 joint publications

Hatice Odabas

8 joint publications

Goncagul Akdag

8 joint publications

Heves Surmeli